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article under the CC BY-NC-ND licenseAbstract High risk prostate cancer is a deadly disease that needs aggressive treatment. High
risk prostate cancer is often treated with androgen deprivation therapy or combined radiohor-
monotherapy while there is a place for surgery in cases of operable and resectable locally
advanced or high risk disease. This review summarises the results of the different treatment
strategies for locally advanced and high risk prostate cancer. Radical prostatectomy monother-
apy or in combination with radiotherapy and/or hormonal treatment are analysed. They show
that radical prostatectomy is an effective treatment modality for these tumours. After sur-
gery, the results of the pathology and the follow-up of serum PSA may indicate the need of
additional adjuvant or salvage treatment strategies.
ª 2014 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
For many years urologists have proposed radical prosta-
tectomy (RP) as the gold standard for localised prostate
cancer in often low risk and intermediate risk prostate
cancer patients. Today, surgery for these patients is often
considered overtreatment. Since the issue of high risk
prostate cancer, that was often undertreated (with
androgen deprivation therapy or combined radiotherapyl@uzleuven.be.
f Chinese Urological Associa-
.09.009
sian Journal of Urology. Productio
(http://creativecommons.org/liand androgen deprivation therapy), oncologic urologists
have more and more focused on high risk prostate cancer.
Locally advanced prostate cancer has extended clini-
cally beyond the prostatic capsule, with invasion of the
pericapsular tissue, bladder neck, or seminal vesicles, but
without lymph node involvement or distant metastases. It is
referred to as T3eT4 N0 M0 prostatic cancer. High-grade
prostate cancer, also called poorly differentiated prostate
cancer, has Gleason scores from 8 to 10.
Based on preoperative parameters (clinical stage, initial
PSA and Gleason Score), Yossepowitch et al. [1] defined
eight different categories amongst high risk prostate cancer
(HRPC) patients and concluded that these HRPC patients don and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
censes/by-nc-nd/4.0/).
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[2] analysing a multi-institutional database have shown that
there are three distinct categories with different cancer
specific survival rates considering three prognostic param-
eters: initial PSA, clinical stage, and Gleason score. Many
patients classified as being at high risk have pathologically
organ-confined cancer and may be cured by RP alone [1].
Historically, patients with locally advanced disease and
high-grade prostate cancer have not been viewed as good
candidates for RP, due to the high incidence of positive
pelvic lymph nodes and poor long-term survival rates [3,4].
The advent of prostate-specific antigen (PSA) screening and
modern imaging modalities allow early detection of high-
grade tumours. The use of these screening techniques has
led to stage migration and decreased morbidity after RP,
sparking renewed interest in the use of surgery in men with
advanced prostate cancer. Nevertheless, the optimal ther-
apy for patients with locally advanced and high-grade tu-
mours remains unclear.
2. Surgery for locally advanced and high-grade
prostate cancer
Until recently, surgical treatment has not been used in clin-
ical T3eT4 disease and high-grade prostate cancer. Over-
staging (pT2), over-grading, and under-staging (pT4 or pNþ)
are commonclinical errors.Nomogramshavebeendeveloped
to predict the pathologic stage of the disease and seminal
vesicle invasion at RP [5, 6]. In addition, nodal imaging with
computed tomography (CT) scans, seminal vesicle invasion
(SVI) imaging with magnetic resonance imaging (MRI), or
directed needle core biopsies of the nodes or seminal vesicles
canbehelpful in recognising patientswho for some timewere
deemed not to benefit from a surgical approach [7].
The European Association of Urology (EAU) guidelines on
prostate cancer state that RP can best be proposed to pa-
tients with locally advanced prostate cancer when the PSA is
<20 ng/mL,with a clinical stagecT3a, and a biopsyGleason
score 8). However, patients with more advanced or poorly
differentiated tumours are also considered to potentially
benefit from surgery [8]. Surgical treatment in locally
advanced T3 prostate cancer involves a radical prostate
extirpation, including an extended lymph node dissection,
clean apical dissection, neurovascular bundle resection at
the tumour-bearing side, complete resection of the seminal
vesicles, andmost often resection of the bladder neck [9,10].
Increased overall surgical experience results in improved
positive surgical margin rates over time (75% in 1987e1994,
42% in 1995e1999, and 10.4% in 2000e2004) [11].
Extended lymph node dissection (LND) is mainly advised
in locally advanced disease and high-grade prostate cancer,
due to a higher risk of node-positive disease. In older sur-
gical series of cT3 disease, the node-positive rate is be-
tween 27% and 41% [12]. Other series had a much lower rate
of pNþ cases (11%), respectively, probably due to more
accurate and dedicated CT scanning of the pelvis and
methods of patient selection [13]. The percentage of pos-
itive biopsy cores can help to predict lymph node invasion
in patients undergoing RP and extended pelvic LND [14].
The most common postoperative complications are urinary
incontinence and sexual dysfunction, which occurimmediately after RP and tend to improve over time. In
early stages of the disease, the incidence of these com-
plications can be reduced by nerve-sparing surgery. In men
with T3 disease, however, non-nerve-sparing RP must be
carried out at least at the tumour bearing side. Increased
overall surgical experience leads to decreased operative
morbidity and better functional results [15].
3. Locally advanced prostate cancer
3.1. Studies with RP monotherapy
RP monotherapy may be an acceptable treatment option
for cT3 disease. This is true not only in over-staged patients
(pT2), but also in true unilateral pT3a, especially if the
tumour is specimen-confined (R0). In cT3 disease, the
cancer-specific survival (CSS) rate after RP at 5- and 10-year
follow-up is 85%e100% and 57%e72%, respectively. The
overall survival (OS) rate at 5- and 10-year follow-up is
>75% and 60%, respectively [4, 16, 17].
RP monotherapy is an effective treatment in men with
T3 disease, particularly in patients with a serum PSA value
<10 ng/mL and uninvolved lymph nodes and seminal vesi-
cles. Clinical T3a patients with PSA values <10 ng/mL had a
5-year biochemical recurrence-free survival rate exceeding
60% [13]. Other authors evaluated 83 surgically treated
cT3a patients at a mean follow-up of 68.7 months and re-
ported OS and CSS rates of 97.6% and 100%, respectively.
The authors used very strict selection criteria: limited cT3a
on digital rectal examination combined with <T3a on
transrectal ultrasonography [17].
These results support the use of RP monotherapy as a
possible treatment for selected locally advanced prostate
cancer. The possible occurrence of complications is not
seen as a valid reason for not performing RP in cT3 disease
because only few serious events were reported.
3.2. Multimodality treatment
In a substantial number of patients, RP monotherapy will
not result in a definitive cure; therefore, early adjuvant or
late salvage radiation (RT) or hormone treatment (HT)
should be considered.
In a study by Ward et al. [12], 78% of patients eventually
needed adjuvant or salvage RT or HT compared to 56% of
patients in a recent study from Hsu et al. [18]. These studies
reveal excellent 5-, 10-, and 15-year OS and CSS rates,
comparable to those obtained in cT2 patients. In addition,
the Ward and Hsu studies had similar survival rates, with 5-
year CSS rates of 95% and 98.7%, respectively, and 10-year
CSS rates of 90% and 91.6%, respectively [12,18]. Ward
et al. [12] also reported a 15-year CSS rate of 79%.
In a recent study by Gontero et al. [19], RP appears to be
a valid treatment with acceptable morbidity in patients
with locally advanced prostate cancer of any T  3, N0-1.
The 7-year OS and CSS rates were 77% and 90%, respec-
tively; 89.5% of the patients received immediate adjuvant
treatment after RP [19]. This is also the opinion of Lange
[20], who expressed the need for a randomised study
testing the efficacy of RT and RP as initial therapy for
locally advanced prostate cancer. In the meantime, RP
42 H. van Poppelseries revealed survival rates that surpass those for RT
alone and comparable to those of 3 years of androgen-
deprivation therapy combined with external RT.
Two randomised studies compared postoperative RTwith
RP alone for locally advanced prostate cancer. Bolla et al.
[21] reported an improved biochemical progression-free
survival (BPFS) in patients treated with adjuvant post-
operative RT (74% vs. 52.6%, p < 0.0001) with an extended
follow-up, but no improved cancer specific survival.
Thompson et al. [22] showed that adjuvant postoperative
RT significantly reduced the risk of PSA relapse (median PSA
relapse-free survival, 10.3 years for RT vs. 3.1 years for
observation, p < 0.001) and disease recurrence (median
recurrence-free survival, 13.8 years for RT vs. 9.9 years for
observation, p Z 0.001).
Our belief that RP has a place in the treatment of locally
advanced prostate cancer is supported by a few studies
conducted in the United States [23e28]. Another study
showed that patients who underwent RP (n Z 72) for cT4
disease had a better survival than those who received HT
alone or RT alone and comparable survival to that of men
who received RT plus HT [29].
4. High-grade prostate cancer
4.1. Studies with radical prostatectomy
monotherapy
A Gleason score 7 in an RP specimen, when the biopsy
specimen was scored from 8 to 10, is defined as pathologic
downgrading. A recent study reported that the incidence of
downgrading was 45% and that downgraded patients had an
increased BPFS probability (56% vs. 27%). Moreover, pa-
tients with a biopsy Gleason score of 8 and a clinical stage
of T1c were more likely to be downgraded and, thus, had a
better BPFS probability. Of these patients, 64% were free of
biochemical or clinical recurrence [30]. In a study from
Manoharan et al. [31], the incidence of downgrading was
reported as 31%, with patients having a lower biochemical
recurrence rate (32% vs. 41%). Grossfeld et al. [32] assessed
the surgical outcome of 114 men with high-grade prostate
cancer and noted downgrading in 38% of the patients. In a
study from Bastian et al. [33], 34% of men in the patient
cohort were downgraded and had a 5- and 10-year esti-
mated BPFS of 62% and 38%, respectively. In the Shared
Equal Access Research Cancer Hospital (SEARCH) database,
55% of men were downgraded and had a 5- and 10-year
estimated BPFS of 34% and 34%, respectively.
These results suggest that one third of patients with a
biopsy Gleason score 8 may in fact have a specimen
Gleason score 7 with better prognostic characteristics.
Therefore, refusing RP, which is an excellent treatment for
those patients, would be incorrect. A number of reports
have addressed the success rates of RP monotherapy in
high-grade cancer. Donohue et al. [30] examined the
outcome of RP monotherapy in 238 patients with high-
grade prostate cancer and found a 5- and 10-year BPFS of
51% and 39%, respectively, in agreement with rates re-
ported in other series [34e36]. Mian et al. [37] assessed
the outcome of patients with a specimen Gleason score 8
treated with RP alone. The reported 5- and 7-year BPFS of71% and 55%, respectively, are better than the rates re-
ported by Donohue et al. [30] and other studies [34e36]. In
addition, the rate of lymph node metastasis was only 6%
compared to 20% in the Donohue study. In a study analysing
79 high-grade patients treated with RP at a mean follow-up
of 55 months, the overall biochemical failure rate was 38%
(41% if Gleason score was 8, and 32% if it was 7).
Manoharan et al. [31] concluded that RP is a reasonable
treatment option for patients with a biopsy Gleason
score 8 and clinical stage T1e2, especially if their PSA
level is 20 ng/mL.
Serni et al. [38] evaluated the outcome of 116 patients
with Gleason scores 8 who underwent RP. The 3- and 5-
year progression-free survival rates for all patients were
84.6% and 78.1%, respectively. The 5-year BPFS for those
with Gleason scores of 8 and 9 were 72.1% and 38.2%,
respectively (p  0.05).
Bastian et al. [33] reviewed the data of men with
Gleason scores of 8e10 treated with RP at the Johns Hop-
kins Hospital (n Z 220; 3.8% of the total cohort) and those
within the SEARCH database (n Z 149; 7.7% of the total
cohort). The authors reported 5- and 10-year estimated
BPFS rates of 40% and 27%, respectively, for the Johns
Hopkins cohort, and 32% and 28%, respectively, for those
within the SEARCH database. In conclusion, patients un-
dergoing RP with biopsy Gleason scores of 8e10 do not
necessarily have a poor prognosis. Although most high-
grade tumours extend outside the prostate, those that
are confined to the prostate at histopathologic examination
have a good prognosis after RP [39].
PSA screening enables detection of high-grade tumours
with smaller volume at an earlier stage, thus improving the
organ- and specimen-confined disease rates [37]. Two
separate studies reported the incidence of organ-confined
disease at 26% [34] and 31% [37]. Mian et al. [37] showed
that patients with organ- and specimen-confined disease
had a higher 5-year disease-free survival rate than those
with non-specimen-confined disease (82%, 84%, and 50%,
respectively). A favourable disease-free survival could be
expected in patients treated with RP alone, especially if
the cancer is confined to the prostate or surgical specimen.
Bastian et al. [33] found higher 5- and 10-year estimated
BPFS among men with organ-confined disease and negative
surgical margins (79% and 50% vs. 40% and 27% for the entire
cohort, respectively).
Serni et al. [38] reported that the incidence of organ-
confined node-negative disease is 11.2%. At a mean
follow-up of 46 months, all patients with organ-confined
disease were free of biochemical recurrence. These re-
sults emphasise the importance of early diagnosis and
indicate that intracapsular tumours are less likely to met-
astasise, even with a high Gleason score. The incidence of
pT3, specimen-confined, node-negative disease (29.3%)
was greater than those has been reported in other series
[35,36,40]. Serni et al. [38] reported that the 5-year BPFS
rates for pT3a specimen-confined, pT3a non-specimen-
confined, and pT3b disease were 68.2%, 53.3%, and 10.5%,
respectively. These results show that high-grade tumours
that have invaded the capsule can also be cured by surgery.
The finding of negative margins improves the BPFS,
although the presence of histologically confirmed SVI in-
dicates a poor prognosis. Using the anterograde technique
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risk patients and increases the pT3a specimen-confined
rate [38].
Grossfeld et al. [32] noted a 5-year disease-free survival
rate of 47% in high-grade patients with PSA 10 ng/mL vs.
19% in those with PSA >10 ng/mL. Patients with high-grade
disease might therefore be appropriate candidates for RP if
the PSA value is 10 ng/mL and the % PBCs <66%.
A study by Hurwitz et al. [41] assessed the surgical
outcome of 168 men with high-grade prostate cancer. Pa-
tients with PSA <10 ng/mL and % PBCs <50% had a 5-year
BPFS probability of 67% vs. 23% for all other patients.
Both studies suggest that the PSA value and the % PBCs can
be helpful in selecting men with high-grade prostate cancer
most likely to benefit from RP. Interobserver variations in
pathologic staging are well documented and need
consideration.
4.2. Comparison among conservative treatment,
RP, and RT
Tewari et al. [42] compared the use of conservative treat-
ment (n Z 197), RP (n Z 119), and RT (n Z 137) in high-
grade prostate cancer. The study was conducted as a sin-
gle institutional, retrospective cohort study including 453
patients with biopsy Gleason scores 8. Using propensity-
scoring analysis, the median OS rate for conservative
treatment was 5.2 year, for RT it was 6.7 year, and for RP it
was 9.7 year. Median CSS was 7.8 year for conservative
treatment and >14 year for both RT and RP. The risk of
cancer-specific death after RP was 68% lower than after
conservative treatment and 49% lower than after RT
(p < 0.001 and p < 0.053, respectively).
From a recently published large observational study
analysing data of the Swedish prostate cancer registry, it
was shown that after 15 years surgery in men with non-
metastatic prostate cancer leads to better survival than
does radiotherapy. The authors concluded that younger
men and those with less comorbidity who have intermedi-
ate or high risk localised prostate cancer may have a
greater benefit from surgery [43].
4.3. Multimodality treatment
To achieve complete elimination of local disease and to
improve outcomes, multimodality treatment is often rec-
ommended for high-grade prostate cancer. Lau et al. [34]
reported that treatment with adjuvant HT in patients
with high-grade cancer appears to improve the 10-year
progression-free survival rate after RP but does not signif-
icantly reduce death from prostate cancer within 10 year.
Postoperative RT in the treatment of high-grade prostate
cancer may improve outcomes, but its role remains
controversial. In men with high-grade prostate cancer, Do
et al. [44] reported a 5-year BPFS of 65% in patients treated
with RP and postoperative RT compared with 30% after RP
alone, and 25% after RT alone. The clinical progression-free
survival was also improved with the addition of post-
operative RT compared with RP and RT alone (80%, 60%, and
35%). Other reports have indicated that adjuvant RT is
associated with a lower risk of biochemical recurrence,although there is no significant improvement in CSS rates at
10-year follow-up [34, 35]. Loeb et al. [26] reviewed the
data of 288 men who underwent RP, 254 of whom were
high-risk patients (cT2b, a Gleason score of 8e10,
PSA >15 ng/mL). For the high-risk patients, the 10-year
progression-free survival, CSS rate, and OS rate were 37%,
88%, and 75%, respectively. Patients received adjuvant or
salvage treatment when needed.
Bastian et al. [33] recommend multimodality therapy for
high-grade tumours. This often consists of RT plus HT;
however, newer possibilities exist, such as a combination of
RP plus neoadjuvant or adjuvant (chemo)-HT or RP with
adjuvant RT [33]. A recent paper reviews the use of a
combination of external-beam RT and systemic agent with
RP for HRPC patients [45].
5. Conclusion
It is very likely that RP is an effective form of treatment for
locally advanced and high-grade tumours. The best candi-
dates for RP are patients who were clinically over-staged or
over-graded by the puncture biopsy and whose tumours
were subsequently found to be locally confined, to have
limited extracapsular extension, or to be moderately
differentiated. However, this does not mean that more
advanced stages or grades are necessarily a contraindica-
tion for surgery. In younger patients, even advanced tu-
mours and Gleason scores 8 are best managed initially by
surgery. The increased use of nomograms and modern im-
aging techniques is helpful in recognising patients with
locally advanced disease or high-grade disease most likely
to benefit from surgical treatment.
Urologists must use the pathologic results, which indi-
cate the need for additional postoperative treatment, to
improve the final outcome. Further studies will be required
to clarify whether neoadjuvant (chemo)-HT, adjuvant/
salvage (chemo)-HT, and adjuvant/salvage RT can improve
the results of RP.
5.1. Locally advanced prostate cancer
RP monotherapy provides tumour control in selected pa-
tients with cT3 disease, with 5- and 10-year CSS rates of
>85% and 57%, respectively. The OS rates at 5- and 10-year
are >75% and 60%, respectively.
In well-selected patients, RP, combined with adjuvant or
salvage treatment when needed, may result in better out-
comes than RT alone, similar to the combination of RT plus
HT therapy. These findings should be confirmed in rando-
mised, prospective studies.
5.2. High-grade prostate cancer
In a recent study, patients with high-grade prostate cancer
who underwent RP monotherapy had 5- and 10-year BPFS
rates of 51% and 39%, respectively. This is in agreement
with rates reported in other series. Studies show that up to
one third of patients with high-grade prostate cancer are
subsequently downgraded and have a better BPFS proba-
bility after RP. Disease-free survival after RP can also be
expected if the cancer is confined to the prostate or
44 H. van Poppelsurgical specimen. PSA value and the % PBCs can be useful
in selecting men with high-grade prostate cancer most
likely to benefit from RP. Patients with high-grade prostate
cancer are likely to be good candidates for multimodality
treatment, often consisting of RP with adjuvant or salvage
RT and HT, although newer treatment combinations are
being tested.Conflicts of interest
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